MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Bracco Features its Mission of 'No Compromise in MRI' at RSNA 2022

By MedImaging International staff writers
Posted on 25 Nov 2022
Print article
Image: The FDA-approved Gadopiclenol injection will be commercialized as VUEWAY (Photo courtesy of Bracco)
Image: The FDA-approved Gadopiclenol injection will be commercialized as VUEWAY (Photo courtesy of Bracco)

Bracco Diagnostics Inc. (Monroe Township, N.J., USA), the US subsidiary of Bracco Imaging S.p.A., is featuring the recently FDA-approved Gadopiclenol Injection, a novel, highly stable macrocyclic gadolinium-based contrast agent (GBCA), commercialized as VUEWAY (gadopiclenol) injection by Bracco, among a robust line of imaging products, devices, and support solutions, at RSNA 2022.

Bracco is offering several engagement opportunities at RSNA 2022, including Meet and Connect with Peers during a media briefing that will profile 'No Compromise in Magnetic Resonance Imaging (MRI),' to summarize the company's comprehensive support and education, and spotlight the new category that VUEWAY injection creates for imaging agents. Bracco is also offering ‘Celebrate our Leaders on the Horizon’, an exclusive radiology residency program in which continuing education scholarships are awarded to five radiology residents whose submitted research papers are selected for publication in a special supplement to Applied Radiology. Visitors to the Bracco booth can experience its innovation throughout all diagnostic imaging modalities, including its Smartinject contrast delivery platforms, innovative informatics solutions, and best-in-class service offerings.

“We can think of no better venue to further educate and connect with our peers and industry partners than at RSNA, the world's largest medical imaging forum,” said Cosimo De Pinto, Senior Vice President, Sales and Marketing at Bracco Diagnostics Inc. “We've taken this year's congress theme of 'empowering patients and partners in our care' to heart, working hard to ensure our customers can look deeper and remain confident in the care they provide their patients. We are united in driving forward the next generation of diagnostic solutions as we unveil VUEWAY injection and work to fulfill our own mission of 'No Compromise in MRI'.”

Related Links:
Bracco Diagnostics Inc.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
P20 Elite
Thyroid Shield
Standard Thyroid Shield
New
Pre-Op Planning Solution
Sectra 3D Trauma

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more